Merck & Co., Inc. (ETR:6MK)
Germany · Delayed Price · Currency is EUR | Market Cap | 272.16B +52.1% |
| Revenue (ttm) | 57.04B +2.9% |
| Net Income | 7.75B -48.8% |
| EPS | 3.10 -48.0% |
| Shares Out | n/a |
| PE Ratio | 35.12 |
| Forward PE | 20.20 |
| Dividend | 2.89 (2.66%) |
| Ex-Dividend Date | Jun 15, 2026 |
| Volume | 1,688 |
| Open | 110.18 |
| Previous Close | 108.80 |
| Day's Range | 109.88 - 112.36 |
| 52-Week Range | 66.40 - 112.36 |
| Beta | 0.22 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 4, 2026 |
About Merck & Co.
Merck & Co., Inc. operates as a healthcare company worldwide. It offers human health pharmaceutical for various areas under the Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23, Bridion, Prevymis, Dificid, Zerbaxa, Winrevair, Adempas/ Verquvo, Ohtuvayre, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. The company also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock produ... [Read more]
Financial Performance
In 2025, Merck & Co.'s revenue was $65.01 billion, an increase of 1.31% compared to the previous year's $64.17 billion. Earnings were $18.25 billion, an increase of 6.64%.
Financial numbers in USD Financial StatementsNews
The Big 3: JPM, DHR, MRK
Dan Deming talks joins today's Big 3 and highlights JPMorgan Chase (JPM) as shares touch new record highs. He sees Danaher (DHR) as a candidate for a continuing breakout, noting a similar pattern in M...
Merck says FDA approves Keytruda and Keytruda Qlex in combo with Trodelvy
Merck (MRK) announced the U.S. FDA approved Keytruda and Keytruda Qlex, each in combination with Trodelvy, Gilead’s (GILD) Trop-2-directed antibody-drug conjugate, for the first-line treatment of adul...
FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), each with Trodelvy® (sacituzumab govitecan-hziy) as First-Line Treatment of PD-L1+ (CPS ≥10) Advanced Triple-Negative Breast Cancer (TNBC)
RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the U.S. Food and Drug Administration (FDA) approved KEYTRUDA® (pe...
Merck says EC approves Keytruda plus Padcev combination
Merck (MRK) announced that Keytruda, Merck’s anti-PD-1 therapy, in combination with Padcev, an antibody-drug conjugate, is approved in the European Union, as neoadjuvant treatment and then continued a...
European Commission Approves KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) as First PD-1 Inhibitor Plus Antibody-Drug Conjugate Regimen for Adults With Cisplatin-Ineligible Resectable Muscle-Invasive Bladder Cancer
RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that KEYTRUDA® (pembrolizumab), Merck's anti-PD-1 therapy, in combination with P...
Merck initiated with an Outperform at CICC
CICC initiated coverage of Merck (MRK) with an Outperform rating and $138 price target
Merck and Mae Partner to Expand Doula Workforce and Address Maternal Health Disparities in High-Risk U.S. Markets
NEW YORK--(BUSINESS WIRE)--Merck, through the company's Merck for Mothers initiative, and Mae are collaborating on a multi-state effort to expand and sustain the community-based doula workforce, with ...
Merck's bowel disease drug meets main goal in late-stage trial
Merck said on Monday its drug met the main goal in a late-stage trial testing it in patients with a type of inflammatory bowel disease.
Merck announces ‘positive’ results from Phase 3 trial of tulisokibart
Merck (MRK) announced positive topline results from the Phase 3 ATLAS-UC induction-only study evaluating tulisokibart, an investigational humanized monoclonal antibody targeting tumor necrosis factor-...
Merck's Tulisokibart Met Primary and Key Secondary Endpoints in the Phase 3 ATLAS-UC Induction-only Study in Patients With Moderately to Severely Active Ulcerative Colitis (UC)
RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced positive topline results from the Phase 3 ATLAS-UC induction-only ...
Merck says FDA approves additional indication for Capvaxive
Merck (MRK) announced that the U.S. FDA has approved an expanded indication for Capvaxive to include children and adolescents aged 2 through 17 years who have completed a primary pediatric…
Merck's pneumococcal vaccine wins US approval for high-risk children, teens
Drugmaker Merck said on Thursday the U.S. health regulator has approved an expanded use of its pneumococcal vaccine for children and teenagers who face a higher risk of catching the bacterial diseas...
U.S. FDA Approves an Additional Indication for CAPVAXIVE® (Pneumococcal 21-valent Conjugate Vaccine) in Children and Adolescents Aged 2 through 17 at Increased Risk for Pneumococcal Disease
RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--U.S. FDA Approves an Additional Indication for CAPVAXIVE® (Pneumococcal 21-valent Conjugate Vaccine).
Study Reveals Dog Owners and Veterinarians See Challenges in Treating Allergic Skin Disease, Highlighting a Need for a Targeted Rapid Onset Treatment for Dogs of All Ages
RAHWAY, N.J.--(BUSINESS WIRE)--Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK), today announced r...
Protillion Biosciences Announces Drug Discovery Collaboration with Merck
CARLSBAD, Calif.--(BUSINESS WIRE)--Protillion Biosciences, Inc., a leader in lab-in-the-loop AI drug design, today announced the signing of a multi-target discovery collaboration and license agreement...
FDA approves Keytruda-Welireg combination for adjuvant treatment of ccRCC
Merck (MRK) announced the U.S. Food and Drug Administration approved KEYTRUDA and KEYTRUDA QLEX, Merck’s anti-PD-1 therapies, each in combination with WELIREG, Merck’s first-in-class, oral hypoxia-ind...
FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each With WELIREG® (belzutifan), for Adjuvant Treatment of Certain Patients With Clear Cell Renal Cell Carcinoma (ccRCC)
RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--FDA Approves KEYTRUDA® and KEYTRUDA QLEXTM , Each With WELIREG®, for Adjuvant Treatment of Certain Patients With ccRCC.
FDA approves Merck’s belzutifan with Keytruda for renal cell carcinoma
The Food and Drug Administration approved Merck’s (MRK) belzutifan in combination with Keytruda for the adjuvant treatment of adults with renal cell carcinoma with a clear cell component at intermedia...
Healthcare ETFs: From Broad Exposure to Big Breakthroughs
With AI and space dominating many of the market's most popular investment themes, it can be difficult to find differentiated opportunities. Healthcare is often viewed as one of the more defensive sect...
Merck Animal Health to acquire Targan
Merck (MRK) division Merck Animal Health has signed a definitive agreement to acquire Targan, a privately held innovator in developing and commercializing biodevice solutions to improve performance ou...
Merck Animal Health to Acquire TARGAN
RAHWAY, N.J.--(BUSINESS WIRE)--Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK), today announced t...
Merck & Co. Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026
Transformation is ahead of schedule, with strong progress in oncology, HIV, and ophthalmology. The pipeline is robust, featuring differentiated ADCs, mRNA therapies, and novel cardiometabolic and immunology assets, with over 20 late-stage assets expected to drive significant growth.
The space race is coming for pharma: Why drug development is heading to lower Earth orbit
Industries from semiconductors to fiber-optic cables stand to benefit from space research and manufacturing, but experts told CNBC that medicine could see the most immediate disruption. A flurry of co...
Merck, Gilead announce discontinuation of Phase 3 KEYNOTE-D46/EVOKE-03 study
Merck (MRK) and Gilead Sciences (GILD) announced the discontinuation of the Phase 3 KEYNOTE-D46/EVOKE-03 study investigating Gilead’s Trodelvy in combination with KEYTRUDA, Merck’s anti-PD-1 therapy, ...